Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform Eisai Jun 03, 2024 14:22 HKT/SGT Read More
エーザイ、TIME 誌による「最も影響力のある 100 社（TIME100 MOST INFLUENTIAL COMPANIES）」に選定 Eisai Jun 03, 2024 14:00 JST Read More
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea Eisai May 28, 2024 14:19 HKT/SGT Read More
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 Eisai May 23, 2024 17:07 HKT/SGT Read More
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status Eisai May 15, 2024 10:19 HKT/SGT Read More
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures Eisai May 13, 2024 16:06 HKT/SGT Read More
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg BioMed X Institute Apr 30, 2024 17:00 HKT/SGT Read More
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) Eisai Apr 18, 2024 09:53 HKT/SGT Read More
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan Eisai Apr 17, 2024 15:17 HKT/SGT Read More
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics Eisai Apr 03, 2024 15:24 HKT/SGT Read More
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA Eisai Apr 01, 2024 08:39 HKT/SGT Read More
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical Eisai Mar 29, 2024 14:51 HKT/SGT Read More
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture Eisai Mar 29, 2024 14:19 HKT/SGT Read More
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 Eisai Mar 29, 2024 13:32 HKT/SGT Read More
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace Eisai Mar 21, 2024 15:10 HKT/SGT Read More
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients Eisai Mar 06, 2024 16:47 HKT/SGT Read More
エーザイ、第18回アルツハイマー・パーキンソン病学会（AD/PDTM2024）において、レカネマブをはじめとするアルツハイマー病に関する最新研究成果を発表 Eisai Feb 29, 2024 11:00 JST Read More
